Melanoma is a malignant tumor derived from epidermal melanocytes, and it is known for its
aggressiveness, therapeutic resistance, and predisposition for late metastasis. Very late …

Introduction The transmembrane α 4 β 1 integrin receptor, or very-late antigen 4 (VLA-4), is
associated with tumor metastasis and angiogenesis, the development of chemotherapeutic …

Biomedical imaging techniques such as skeletal survey and 18F-fluorodeoxyglucose
(FDG)/Positron Emission Tomography (PET) are frequently used to diagnose and stage …

Malignant melanoma is a highly aggressive cancer, and the incidence of this disease is
increasing worldwide at an alarming rate. Despite advances in the treatment of melanoma …

Abstract Very late antigen 4 (VLA-4; also called integrin α4β1) is overexpressed in
melanoma tumor cells with an active role in tumor growth, angiogenesis, and metastasis …

Despite advances in cancer treatment over the past few decades, metastatic disease
remains the primary cause of morbidity and mortality. Recent reports suggest the formation …

Integrin α4β1 (also called very late antigen-4 or VLA-4) plays an important role in tumor
growth, angiogenesis and metastasis, and there has been increasing interest in targeting …

DOTA is commonly used for radiometal chelation in molecular imaging. Yet in the absence
of a radiometal, DOTA is hypothesized to promote renal clearance of 18F-labeled peptide …

68Ga-NOTA-WL12 is a peptide-based PET imaging agent. We conducted a first-in-human
study of 68Ga-NOTA-WL12 for PET to study the in vivo biodistribution, metabolism, radiation …

Pancreatic cancer is highly malignant and has a five-year survival rate of 5% due to an early
lymph node, nerve, and vascular metastasis. Integrin α3β1 (also called very late antigen-3 …